Primary care practitioners (PCPs) are central to managing major depressive disorder (MDD), a leading cause of global disability. However, the translation of research into practice is often hindered by poor reporting of interventions. This study aims to systematically evaluate the completeness of intervention reporting in randomized controlled trials (RCTs) concerning MDD treatments delivered by PCPs, using the Template for Intervention Description and Replication (TIDieR) checklist. It also seeks to identify study characteristics associated with higher-quality reporting to inform future research standards.
The authors conducted a cross-sectional metaresearch study, systematically searching six electronic databases for RCTs published up to October 7, 2024. Eligible studies involved adult patients with MDD receiving any intervention from PCPs. Two authors independently screened records, extracted data and assessed the reporting completeness of each intervention against the 12-item TIDieR checklist. Univariate linear regression models were used to explore associations between study characteristics and TIDieR completion scores.
Across 22 included RCTs describing 34 interventions, the median TIDieR completion score was 55.64%. No intervention was fully described according to all 12 TIDieR items. While the intervention’s name was always provided (100% compliance), the mode of delivery was the least reported item (20.59%). Pharmacological interventions were the most frequent category (55.88%). Larger trial size was a predictor of better reporting, whereas reporting of participants’ consent was associated with poorer reporting.
The limited sample size (22 studies) reduces the statistical power and generalizability of our regression analyses. Many included studies were over 20 years old, potentially not reflecting contemporary reporting standards. The variability in diagnostic criteria for MDD across studies also complicates direct comparisons. These limitations highlight the need for greater standardization in both diagnostic and reporting practices in psychiatric research to ensure findings are comparable and replicable. TIDieR itself does not assess intervention quality, only reporting completeness.
The suboptimal and inconsistent reporting of interventions for MDD severely impedes their replication in clinical practice and slows the implementation of evidence-based care. Clinicians cannot confidently apply interventions when crucial details on delivery, tailoring and fidelity are missing. The findings serve as a call to action for researchers, journal editors and peer reviewers to mandate and adhere to reporting guidelines like TIDieR. This would enhance the transparency, utility and ultimate impact of clinical research in primary care settings.
MDD is a leading contributor to the global burden of disease, with most patients managed in primary care. Poor research reporting acts as a barrier to disseminating effective treatments, meaning patients may not benefit from scientific advances. By improving the clarity and completeness of intervention descriptions, the research community can better support PCPs in delivering effective, evidence-based care. This, in turn, can lead to improved mental health outcomes at a population level, reducing the profound societal impact of depression.
This study provides a novel, systematic evaluation of intervention reporting quality specifically for MDD management within the crucial context of primary care. By applying the TIDieR checklist, it quantifies specific reporting gaps – such as the near-universal failure to describe the mode of delivery – that directly impact the replicability of research. The findings uniquely highlight that pharmacological trials dominate this research landscape, while other modalities like psychotherapy are underrepresented. The work underscores the urgent need for improved reporting standards to bridge the gap between research and clinical practice.
